Effect of Potassium Magnesium Citrate and Vitamin B-6 Prophylaxis for Recurrent and Multiple Calcium Oxalate and Phosphate Urolithiasis.
10.4111/kju.2014.55.6.411
- Author:
S V Krishna REDDY
1
;
Ahammad Basha SHAIK
;
Suneel BOKKISAM
Author Information
1. Department of Urology, Narayana Medical College and Hospital, Nellore, India. vijaya.nel@gmail.com
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords:
Calcium oxalate;
Potassium-magnesium citrate;
Pyridoxine;
Urolithiasis
- MeSH:
Calcium Oxalate*;
Citric Acid*;
Follow-Up Studies;
Humans;
Hydrogen-Ion Concentration;
Magnesium*;
Potassium Citrate;
Potassium*;
Prospective Studies;
Pyridoxine;
Recurrence;
Urolithiasis*;
Vitamins*
- From:Korean Journal of Urology
2014;55(6):411-416
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To study the effects of long-term treatment with potassium magnesium citrate and vitamin B-6 prophylaxis (Urikind-KM6; 1,100-mg potassium citrate, 375-mg magnesium citrate, and 20-mg pyridoxine hydrochloride/5 mL) every 8 hours over 3 years. MATERIALS AND METHODS: A total of 247 patients with recurrent idiopathic hypocitraturia with or without hyperuricosuria and randomized controls were studied prospectively for 3 years. The total patients were divided into three groups. Control group 1 consisted of 61 patients (24.7%) who had moderate to severe hypocitraturia with or without hyperuricosuria and were recurrent stone formers but discontinued prophylaxis because of drug intolerance within 1 month of therapy. Control group 2 constituted 53 patients (21.5%) who were first-time stone formers and who had mild hypocitraturia with or without hyperuricosuria and were not put on prophylactic therapy and were followed for 3.16+/-0.08 years. Control group 3 constituted 133 patients (54.8%) who were recurrent stone formers who had moderate to severe hypocitraturia with or without hyperuricosuria and were put on prophylaxis therapy and were followed for 3.16+/-0.08 years. All patients were followed up at 6-month intervals. RESULTS: Potassium magnesium citrate prophylaxis produced a sustained increase in 24-hour urinary citrate excretion from initially low values (221.79+/-13.39 mg/dL) to within normal to high limits (604.04+/-5.00 mg/dL) at the 6-month follow-up. Urinary pH rose significantly from 5.62+/-0.2 to 6.87+/-0.01 and was maintained at 6.87+/-0.01. The stone recurrence rate declined from 3.23+/-1.04 per patient per year to 0.35+/-0.47 per patient per year. CONCLUSIONS: Potassium magnesium citrate prophylaxis was effective in reducing the recurrence of calcium oxalate and phosphate urolithiasis.
